• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Relmada Therapeutics Inc.

    6/22/26 5:32:55 PM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RLMD alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Relmada Therapeutics, Inc.

    (Name of Issuer)


    Common Stock, par value $0.001 per share

    (Title of Class of Securities)




    75955J402

    (CUSIP Number)
    06/16/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    75955J402


    1Names of Reporting Persons

    Millennium Management LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,567,952.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,567,952.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,567,952.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.4 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP Number(s):
    75955J402


    1Names of Reporting Persons

    Millennium Group Management LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,567,952.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,567,952.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,567,952.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.4 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP Number(s):
    75955J402


    1Names of Reporting Persons

    Israel A. Englander
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,567,952.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,567,952.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,567,952.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.4 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Relmada Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    2222 Ponce de Leon Blvd., Floor 3, Coral Gables, Florida 33134
    Item 2. 
    (a)Name of person filing:

    Millennium Management LLC Millennium Group Management LLC Israel A. Englander
    (b)Address or principal business office or, if none, residence:

    Millennium Management LLC 399 Park Avenue New York, New York 10022 Millennium Group Management LLC 399 Park Avenue New York, New York 10022 Israel A. Englander c/o Millennium Management LLC 399 Park Avenue New York, New York 10022
    (c)Citizenship:

    Millennium Management LLC - Delaware Millennium Group Management LLC - Delaware Israel A. Englander - United States
    (d)Title of class of securities:

    Common Stock, par value $0.001 per share
    (e)CUSIP Number(s):

    75955J402
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See response to Item 9 on each cover page. After acquiring beneficial ownership of more than 5% of the outstanding Common Stock on June 16, 2026, the reporting persons ceased to be beneficial owners of more than 5% of the outstanding Common Stock by the date of this filing.
    (b)Percent of class:

    See response to Item 11 on each cover page.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See response to Item 5 on each cover page.

     (ii) Shared power to vote or to direct the vote:

    See response to Item 6 on each cover page.

     (iii) Sole power to dispose or to direct the disposition of:

    See response to Item 7 on each cover page.

     (iv) Shared power to dispose or to direct the disposition of:

    See response to Item 8 on each cover page. The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    See Exhibit I
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Millennium Management LLC
     
    Signature:/s/ Gil Raviv
    Name/Title:Gil Raviv, Global General Counsel
    Date:06/18/2026
     
    Millennium Group Management LLC
     
    Signature:/s/ Gil Raviv
    Name/Title:Gil Raviv, Global General Counsel
    Date:06/18/2026
     
    Israel A. Englander
     
    Signature:/s/ Israel A. Englander
    Name/Title:Israel A. Englander
    Date:06/18/2026
    Exhibit Information

    Exhibit I: Joint Filing Agreement, dated as of June 18, 2026, by and among Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.

    Get the next $RLMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RLMD

    DatePrice TargetRatingAnalyst
    6/18/2026$12.00Buy
    H.C. Wainwright
    3/24/2026$12.00Overweight
    Piper Sandler
    1/23/2026$8.00Outperform
    Leerink Partners
    12/22/2025$69.00Buy
    Jefferies
    11/19/2025$10.00Neutral → Outperform
    Mizuho
    12/5/2024$23.00 → $1.00Outperform → Neutral
    Mizuho
    9/17/2024$3.50 → $13.00Hold → Buy
    Jefferies
    6/5/2024$3.00 → $2.00Neutral → Sell
    Goldman
    More analyst ratings

    $RLMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program

    Dr. Quirk brings more than 20 years of neuroscience drug discovery and development experience to lead Relmada's sepranolone program, building on his tenure as Chief Scientific Officer at Sage Therapeutics. CORAL GABLES, Fla., June 11, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced the appointment of Michael Quirk, PhD, as Senior Advisor – Sepranolone Program. Dr. Quirk's deep expertise in CNS translational science, neuroactive steroid biology, and clinical development will be instrumental in advancing sepr

    6/11/26 7:00:00 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Relmada Therapeutics to Present at the Jefferies Global Healthcare Conference

    CORAL GABLES, Fla., May 28, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer, will participate in the Jefferies Global Healthcare Conference being held in New York, NY, from June 2-4, 2026. Jefferies Global Healthcare Conference DetailsFormat: Fireside ChatDate: Thursday, June 4, 2026Time: 12:50 PM ETWebcast: Click Here Management will also be available for one-on-one investor meetings during the conference. Please co

    5/28/26 7:00:00 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

    Positive 12-Month Phase 2 data for NDV-01 demonstrated a 95% complete response (CR) rate at any time and a durable 76% CR rate at 12 months in high-risk non-muscle invasive bladder cancer (NMIBC), and a 94% CR rate at any time and a durable 80% CR rate at 12 months in the BCG-unresponsive subpopulation, reinforcing best-in-class potential in NMIBCOn track to initiate Phase 3 RESCUE registrational program in second line (2L) BCG-unresponsive and adjuvant intermediate-risk NMIBC in mid-2026Filed provisional patent application with the USPTO in April 2026 covering NDV-01 pharmaceutical formulations and methods of treatment; if issued, patents claiming priority to the provisional filing would ha

    5/12/26 4:05:00 PM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RLMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Relmada Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Relmada Therapeutics with a rating of Buy and set a new price target of $12.00

    6/18/26 8:20:08 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on Relmada Therapeutics with a new price target

    Piper Sandler initiated coverage of Relmada Therapeutics with a rating of Overweight and set a new price target of $12.00

    3/24/26 8:50:23 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners resumed coverage on Relmada Therapeutics with a new price target

    Leerink Partners resumed coverage of Relmada Therapeutics with a rating of Outperform and set a new price target of $8.00

    1/23/26 8:21:07 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RLMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Traversa Sergio bought $113,300 worth of shares (27,500 units at $4.12), increasing direct ownership by 2% to 1,300,000 units (SEC Form 4)

    4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)

    12/16/25 9:30:49 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Shenouda Maged bought $48,060 worth of shares (11,665 units at $4.12), increasing direct ownership by 1% to 800,000 units (SEC Form 4)

    4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)

    12/16/25 9:30:24 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by CA and CO Ence Chuck

    4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)

    12/16/25 9:30:04 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RLMD
    Financials

    Live finance-specific insights

    View All

    Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

    Positive 12-Month Phase 2 data for NDV-01 demonstrated a 95% complete response (CR) rate at any time and a durable 76% CR rate at 12 months in high-risk non-muscle invasive bladder cancer (NMIBC), and a 94% CR rate at any time and a durable 80% CR rate at 12 months in the BCG-unresponsive subpopulation, reinforcing best-in-class potential in NMIBCOn track to initiate Phase 3 RESCUE registrational program in second line (2L) BCG-unresponsive and adjuvant intermediate-risk NMIBC in mid-2026Filed provisional patent application with the USPTO in April 2026 covering NDV-01 pharmaceutical formulations and methods of treatment; if issued, patents claiming priority to the provisional filing would ha

    5/12/26 4:05:00 PM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026

    CORAL GABLES, Fla., May 06, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced plans to host a conference call and webcast on Tuesday, May 12, 2026 at 4:30 PM ET to discuss financial results for the first quarter ended March 31, 2026, and recent business progress. Conference Call and Webcast Information: Date: Tuesday, May 12, 2026 at 4:30 PM ETParticipant Dial-in (US): 1-800-717-1738Participant Dial-in (International): 1-646-307-1865Webcast Access: Click Here A replay of the webcast will be available in the

    5/6/26 7:00:00 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update

    Positive 12-month Phase 2 data for NDV-01 in non-muscle invasive bladder cancer (NMIBC) demonstrated a 95% complete response (CR) rate at any time and a durable 76% CR rate at 12 months, with favorable safety profileCompleted an oversubscribed $160 million PIPE financing led by leading healthcare investors in March 2026, strengthens balance sheet to support NDV-01 Phase 3 developmentOn track to initiate Phase 3 RESCUE registrational program in second line (2L) BCG-unresponsive and adjuvant intermediate-risk NMIBC in mid-2026Cash balance of $93.0 million as of December 31, 2025, plus gross proceeds of $160 million from March 2026 PIPE expected to fund operations through 2029, including comple

    3/19/26 4:01:00 PM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RLMD
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Relmada Therapeutics Inc.

    SCHEDULE 13G - RELMADA THERAPEUTICS, INC. (0001553643) (Subject)

    6/22/26 5:32:55 PM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Relmada Therapeutics Inc.

    S-8 - RELMADA THERAPEUTICS, INC. (0001553643) (Filer)

    6/18/26 4:05:44 PM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Relmada Therapeutics Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - RELMADA THERAPEUTICS, INC. (0001553643) (Filer)

    5/28/26 4:59:47 PM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RLMD
    Leadership Updates

    Live Leadership Updates

    View All

    Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program

    Dr. Quirk brings more than 20 years of neuroscience drug discovery and development experience to lead Relmada's sepranolone program, building on his tenure as Chief Scientific Officer at Sage Therapeutics. CORAL GABLES, Fla., June 11, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced the appointment of Michael Quirk, PhD, as Senior Advisor – Sepranolone Program. Dr. Quirk's deep expertise in CNS translational science, neuroactive steroid biology, and clinical development will be instrumental in advancing sepr

    6/11/26 7:00:00 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01

    Dr. Kates' experience as chair of the landmark Phase 3 BRIDGE bladder cancer trial and dedication to patient care will be invaluable to the NDV-01 Phase 3 program Phase 3 program for NDV-01 expected to begin in H1 2026 CORAL GABLES, Fla., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced the appointment of Max Kates, MD, Associate Professor of Urology and Oncology at Johns Hopkins University School of Medicine, to Relmada's Clinical Advisory Board (CAB) to support the development of NDV-01 for the

    10/7/25 7:30:00 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01

    Dr. Lotan's distinguished expertise in bladder cancer care and clinical development brings further scientific acumen to Relmada's NDV-01 program Phase 3 trial for NDV-01 expected to begin in H1 2026 CORAL GABLES, Fla., July 15, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced the appointment of Yair Lotan, MD, a distinguished urologic oncologist, as Chair of Relmada's Clinical Advisory Board (CAB). Dr. Lotan's deep expertise in bladder cancer care and clinical research will be invaluable as Relmada prepa

    7/15/25 8:00:00 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RLMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Traversa Sergio bought $113,300 worth of shares (27,500 units at $4.12), increasing direct ownership by 2% to 1,300,000 units (SEC Form 4)

    4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)

    12/16/25 9:30:49 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Shenouda Maged bought $48,060 worth of shares (11,665 units at $4.12), increasing direct ownership by 1% to 800,000 units (SEC Form 4)

    4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)

    12/16/25 9:30:24 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Operating Officer Kelly Paul Edward bought $198,000 worth of shares (90,000 units at $2.20), increasing direct ownership by 22% to 502,295 units (SEC Form 4)

    4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)

    11/6/25 7:30:02 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RLMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Relmada Therapeutics Inc.

    SC 13G/A - RELMADA THERAPEUTICS, INC. (0001553643) (Subject)

    11/14/24 9:41:31 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Relmada Therapeutics Inc. (Amendment)

    SC 13G/A - RELMADA THERAPEUTICS, INC. (0001553643) (Subject)

    3/6/24 4:15:42 PM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Relmada Therapeutics Inc. (Amendment)

    SC 13G/A - RELMADA THERAPEUTICS, INC. (0001553643) (Subject)

    2/14/24 8:53:47 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care